AbSci (ABSI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham maintained a Buy rating on the stock and has a $9.00 price target.
Gil Blum has given his Buy rating due to a combination of factors that highlight AbSci’s strategic positioning and operational resilience. One significant aspect is the company’s proactive approach to mitigating risks associated with tariffs, as they do not foresee any substantial impact from such economic policies. This stability in the face of potential external pressures adds a layer of confidence in their operational outlook.
Furthermore, AbSci’s management has strategically planned to conduct initial studies for their ABS-101 and ABS-201 projects in Australia. This decision effectively circumvents the current uncertainties surrounding the FDA, ensuring that their research and development timelines remain on track. These strategic moves by AbSci’s leadership contribute to a positive outlook, justifying the Buy rating.
Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Cartesian Therapeutics, and Geron. According to TipRanks, Blum has an average return of -17.5% and a 27.02% success rate on recommended stocks.